JenaValve names Kilcoyne as CEO | Personnel Moves – January 15, 2019

JenaValve Technology said today that it named former ReVision Optics prez & CEO John Kilcoyne as its new chief executive officer, effective immediately, replacing Dr. Victoria Carr-Brendell, who has taken up an executive leadership position with Sonova Holding AG (SIX:SOON). Prior to his time at ReVision Optics, Kilcoyne served as prez & CEO at Micrus Endovascular where he led the company through an initial public offering in 2005 and an acquisition by Johnson & Johnson in 2010. He has also held positions at Solace Therapeutics and Endonetics, Irvine, Calif.-based JenaValve said. “I am pleased to have the opportunity to lead JenaValve, and I look forward to working with the team to bring new, innovative solutions to the transcatheter valve market. Data from past and ongoing trials clearly indicate the strong potential that the JenaValve technology can greatly improve the health of patients with aortic stenosis and aortic regurgitation. Our focus in 2019 is on completing the current clinical development programs and gaining commercial readiness for potential international launch activities under CE mark and U.S. Humanitarian Device Exemption regulatory processes,” Kilcoyne said in a prepared statement. “I am thrilled that John Kilcoyne has agreed to lead our company. In John, we have identified a dynamic and seasoned executive with an extensive background in driving medical businesses through the key stages of growth and value generation. His p...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured apyxmedical biogennix Cardiac Dimensions Cardiovascular Systems Inc. Coorstek Covidien DaVita Inc. Digirad Corp. Endologix ev3 Inc. Integra LifeSciences Intuitive Surgical InVivo Therapeutics Source Type: news